my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
Cambridge scientists are part of a resolution revolution. Building powerful instruments that shatter the physical limits of optical microscopy, they are beginning to watch molecular processes as they happen, and in three dimensions. Here, Professor Clemens Kaminski describes how a new era of super-resolution microscopy has begun.
The developments earned inventors Eric Betzig and William E Moerner (USA) and Stefan Hell (Germany) the 2014 Nobel Prize for Chemistry, and are based on clever physical tricks that work around the problem of light diffraction.
Among the scientists in Cambridge who are using the techniques, Kaminski’s team in the Department of Chemical Engineering and Biotechnology designs and builds super-resolution microscopes to study Alzheimer’s disease. “The technology is based on a conceptual change, a different way of thinking about how we resolve tiny structures. By imaging blobs of light as separate points in time, we are able to discriminate them spatially, and thus prevent image blur.” Their work is funded by the Medical Research Council, Wellcome Trust, Alzheimers Research UK, the Engineering and Physical Sciences Research Council and the Leverhulme Trust.
Fighting cancer: Animal research at Cambridge
Animal research plays an essential role in our understanding of health and disease and in the development of modern medicine and surgical techniques. As part of our commitment to openness, this film examines how mice are helping the fight against cancer. It takes a in-depth look at the faci ... more
Killer T Cell: The Cancer Assassin
How does a Killer T Cell Kill its target?The new film captures the behaviour of cytotoxic T cells – the body’s ‘serial killers’ – as they hunt down and eliminate cancer cells before moving on to their next target. more
PARP-inhibitors: A New Generation of Cancer Drugs
First of new generation of cancer drugs granted European approvalA new drug for ovarian cancer, developed by researchers at the University of Cambridge and AstraZeneca, has become the first of new class of drugs, known as PARP-inhibitors, to be granted approval anywhere in the world. The dr ... more
Nanoparticles used to transport anti-cancer agent to cells
Scientists from the University of Cambridge have developed a platform that uses nanoparticles known as metal-organic frameworks to deliver a promising anti-cancer agent to cells. Research led by Dr David Fairen-Jimenez, from the Cambridge Department of Chemical Engineering and Biotechnology ... more
AI learns the language of chemistry to predict how to make medicines
University of Cambridge researchers have shown that an algorithm can predict the outcomes of complex chemical reactions with over 90% accuracy, outperforming trained chemists. The algorithm also shows chemists how to make target compounds, providing the chemical 'map' to the desired destina ... more
Global Strep A vaccine one step closer
The search for a global Strep A vaccine has narrowed after researchers sequenced the DNA of more than 2000 Group A Streptococcus samples from around the world. Researchers from the Wellcome Sanger Institute, the University of Cambridge, the Peter Doherty Institute for Infection and Immunity ... more
© 1997-2019 LUMITOS AG, All rights reserved
